GERON CORP (GERN)
A
Pipeline Grade
Financial Position (from SEC Filings)
$8.2M
Cash & Equivalents
$62.9M
Quarterly Burn Rate
$808M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
IMETELSTAT SODIUM
RYTELO |
APPROVED | Acute Myeloid Leukemia, Acute Respiratory Tract Infections, Asthma (Diagnosis), Birth Asphyxia, Breast Cancer, Breast Neoplasms, Chronic Lymphoproliferative Diseases, COPD, Diarrhea, Diarrhea Chronic, Essential Thrombocythemia, Hypertension (HTN), Imetelstat, Locally Recurrent or Metastatic Breast Cancer, Lung Cancer, Malaria, Malaria Fever, Multiple Myeloma, Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Myelodysplastic Syndromes, Myelofibrosis, Myeloid Malignancies, Neonatal Sepsis, Neuroblastoma, Non-small Cell Lung Cancer, Phase II, Pneumonia, Polycythemia Vera, Primary Myelofibrosis, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia, Refractory Childhood Acute Myeloid Leukemia, Refractory Childhood Myelodysplastic Syndrome, Refractory Juvenile Myelomonocytic Leukemia, Relapsed Acute Myeloid Leukemia, Secondary Myelofibrosis, Solid Tumor Malignancies |
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT04576156 | A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosi... | PHASE3 | Active Not Recruiting | 327 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.